End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.12 TWD | +0.05% | +0.14% | -.--% |
2019 | Glac Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019 | CI |
2017 | Glac Biotech Co., Ltd. completed the acquisition of Glory Biotech Co., Ltd.. | CI |
Sales 2017 | 80Cr 2.48Cr 206.34Cr | Sales 2018 | 99Cr 3.08Cr 256Cr | Capitalization | 238.09Cr 7.4Cr 616.35Cr |
---|---|---|---|---|---|
Net income 2017 | 5.1Cr 15.86L 13Cr | Net income 2018 | 9.5Cr 29.54L 25Cr | EV / Sales 2017 | 1.37 x |
Net cash position 2017 | 78Cr 2.44Cr 203.03Cr | Net cash position 2018 | 52Cr 1.61Cr 134.04Cr | EV / Sales 2018 | 1.88 x |
P/E ratio 2017 |
42.3
x | P/E ratio 2018 |
25
x | Employees | - |
Yield 2017 |
10% | Yield 2018 |
-
| Free-Float | 0% |
1 day | +0.05% |
Managers | Title | Age | Since |
---|---|---|---|
Chung Wei Kuo
CEO | Chief Executive Officer | - | 05/08/05 |
Sheng Hung Huang
DFI | Director of Finance/CFO | - | 07/14/07 |
Pei Shan Hsieh
CTO | Chief Tech/Sci/R&D Officer | - | 05/08/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wan Lai Cheng
BRD | Director/Board Member | - | 30/08/30 |
Chung Liang Li
BRD | Director/Board Member | 71 | - |
Jung Chin Lin
CHM | Chairman | 70 | 21/08/21 |
- Stock Market
- Equities
- 6553 Stock